ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $8.81 and traded as high as $10.00. ImmuCell shares last traded at $9.79, with a volume of 20,133 shares trading hands.
Analysts Set New Price Targets
Several research firms have recently weighed in on ICCC. Weiss Ratings raised shares of ImmuCell from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Tuesday, August 18th. Wall Street Zen raised shares of ImmuCell to a "strong-buy" rating in a research report on Saturday, June 27th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has an average rating of "Hold".
View Our Latest Report on ICCC
ImmuCell Stock Performance
The company has a current ratio of 4.75, a quick ratio of 2.71 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $88.91 million, a price-to-earnings ratio of 122.39 and a beta of 0.54. The company has a 50-day moving average of $10.58 and a 200-day moving average of $8.81.
ImmuCell (NASDAQ:ICCC - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.15. ImmuCell had a net margin of 2.57% and a return on equity of 2.69%. The firm had revenue of $7.19 million during the quarter, compared to the consensus estimate of $5.40 million.
Insider Activity
In other ImmuCell news, CEO Boekhorst Paul Francis Oliv Te purchased 8,000 shares of the firm's stock in a transaction dated Thursday, June 18th. The stock was acquired at an average cost of $9.49 per share, with a total value of $75,920.00. Following the acquisition, the chief executive officer owned 17,785 shares of the company's stock, valued at approximately $168,779.65. This represents a 81.76% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 5.70% of the company's stock.
Institutional Investors Weigh In On ImmuCell
Institutional investors have recently modified their holdings of the business. Militia Capital Management LLC bought a new position in ImmuCell in the first quarter worth about $114,000. Mesirow Financial Investment Management Inc. boosted its stake in ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company's stock valued at $224,000 after acquiring an additional 24,303 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of ImmuCell by 3.2% during the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company's stock valued at $355,000 after purchasing an additional 1,749 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of ImmuCell by 4.2% during the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock valued at $500,000 after purchasing an additional 2,907 shares during the last quarter. Institutional investors own 13.47% of the company's stock.
ImmuCell Company Profile
(
Get Free Report)
ImmuCell Corporation NASDAQ: ICCC is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.
The company's flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
